title: Re: Hiremath GK, Steinmetz MP, Krishnaney AA. Is it safe to use recombinant human bone morphogenetic protein in posterior cervical fusion? Spine 2009;34:885-9.
authors.forename: Mislav
authors.initials: M
authors.lastname: Cimic
authors.forename: Tomislav
authors.initials: T
authors.lastname: Smoljanovic
authors.forename: Ivan
authors.initials: I
authors.lastname: Bojanic
mesh_terms: D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage / Q000009:adverse effects*; D002574:Cervical Vertebrae / Q000601:surgery*; D006801:Humans; D011183:Postoperative Complications / Q000453:epidemiology / Q000209:etiology; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects*; D013123:Spinal Fusion / Q000009:adverse effects* / Q000379:methods; D016212:Transforming Growth Factor beta / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2